{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T14:02:41Z","timestamp":1793628161944,"version":"4.5.1"},"reference-count":52,"publisher":"National Academy of Sciences","issue":"49","license":[{"start":{"date-parts":[[2018,5,20]],"date-time":"2018-05-20T00:00:00Z","timestamp":1526774400000},"content-version":"vor","delay-in-days":181,"URL":"http:\/\/www.pnas.org\/site\/aboutpnas\/licenses.xhtml"}],"funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["Fellowship"],"award-info":[{"award-number":["Fellowship"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["HHMI Investigator"],"award-info":[{"award-number":["HHMI Investigator"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["J3220-B19"],"award-info":[{"award-number":["J3220-B19"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 GM07365"],"award-info":[{"award-number":["T32 GM07365"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001117","name":"amfAR, The Foundation for AIDS Research","doi-asserted-by":"publisher","award":["Mathilde Krim Fellowship"],"award-info":[{"award-number":["Mathilde Krim Fellowship"]}],"id":[{"id":"10.13039\/100001117","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1K99AI125065"],"award-info":[{"award-number":["1K99AI125065"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["T32 AI07019"],"award-info":[{"award-number":["T32 AI07019"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1021571"],"award-info":[{"award-number":["OPP1021571"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2017,12,5]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>Cancer immunotherapy is a promising therapeutic intervention. However, complete and durable responses are only seen in a fraction of patients who have cancer. Although cells of the myeloid lineage frequently infiltrate tumors and limit therapeutic success, currently approved immunotherapies primarily target tumor-infiltrating T and natural killer lymphocytes. The inhibitory receptor signal regulatory protein-\u03b1 (SIRP\u03b1) represents a myeloid-specific immune checkpoint that engages the \u201cdon\u2019t eat me\u201d signal CD47. Here, we developed an anti-human SIRP\u03b1 antibody, KWAR23, which in combination with tumor-opsonizing antibodies, greatly augmented neutrophil and macrophage antitumor activity in vitro and in vivo. Thus, KWAR23 may represent a promising candidate for combination therapies and may achieve durable responses in a greater number of patients with cancer.<\/jats:p>","DOI":"10.1073\/pnas.1710877114","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T14:50:19Z","timestamp":1511189419000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":272,"title":["Anti-SIRP\u03b1 antibody immunotherapy enhances neutrophil and macrophage antitumor activity"],"prefix":"10.1073","volume":"114","author":[{"given":"Nan Guo","family":"Ring","sequence":"first","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"},{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Herndler-Brandstetter","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kipp","family":"Weiskopf","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Peter","family":"Volkmer","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson M.","family":"George","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Lietzenmayer","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"McKenna","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswitha J.","family":"Naik","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"McCarty","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjiang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Ring","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Flavell","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520;"},{"name":"Howard Hughes Medical Institute, New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving L.","family":"Weissman","sequence":"additional","affiliation":[{"name":"Institute for Stem Cell Biology and Regenerative Medicine, and Ludwig Center for Cancer Stem Cell Research, Stanford University School of Medicine, Stanford, CA 94305;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: A treatment for the masses","volume":"305","author":"Blattman JN","year":"2004","unstructured":"JN Blattman, PD Greenberg, Cancer immunotherapy: A treatment for the masses. Science 305, 200\u2013205 (2004).","journal-title":"Science"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman I","year":"2011","unstructured":"I Mellman, G Coukos, G Dranoff, Cancer immunotherapy comes of age. Nature 480, 480\u2013489 (2011).","journal-title":"Nature"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"J Larkin, , Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373, 23\u201334 (2015).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"M Reck, , Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med; KEYNOTE-024 Investigators 375, 1823\u20131833 (2016).","journal-title":"N Engl J Med"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf AC","year":"2015","unstructured":"AC Obenauf, , Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520, 368\u2013372 (2015).","journal-title":"Nature"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt JM","year":"2016","unstructured":"JM Pitt, , Resistance mechanisms to immune-checkpoint blockade in cancer: Tumor-intrinsic and -extrinsic factors. Immunity 44, 1255\u20131269 (2016).","journal-title":"Immunity"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ni.3341","article-title":"The development and maintenance of resident macrophages","volume":"17","author":"Perdiguero EG","year":"2016","unstructured":"EG Perdiguero, F Geissmann, The development and maintenance of resident macrophages. Nat Immunol 17, 2\u20138 (2016).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel S","year":"2015","unstructured":"S Ugel, F De Sanctis, S Mandruzzato, V Bronte, Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125, 3365\u20133376 (2015).","journal-title":"J Clin Invest"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc3611","article-title":"Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms","volume":"13","author":"Elinav E","year":"2013","unstructured":"E Elinav, , Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13, 759\u2013771 (2013).","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev-med-051013-052304","article-title":"Regulation of tumor metastasis by myeloid-derived suppressor cells","volume":"66","author":"Condamine T","year":"2015","unstructured":"T Condamine, I Ramachandran, JI Youn, DI Gabrilovich, Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 66, 97\u2013110 (2015).","journal-title":"Annu Rev Med"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt C","year":"2015","unstructured":"C Gebhardt, , Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res 21, 5453\u20135459 (2015).","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasis-initiating breast cancer cells","volume":"528","author":"Wculek SK","year":"2015","unstructured":"SK Wculek, I Malanchi, Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528, 413\u2013417 (2015).","journal-title":"Nature"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt SB","year":"2015","unstructured":"SB Coffelt, , IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal S","year":"2009","unstructured":"S Jaiswal, , CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-associated protein (CD47) and its ligands","volume":"11","author":"Brown EJ","year":"2001","unstructured":"EJ Brown, WA Frazier, Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11, 130\u2013135 (2001).","journal-title":"Trends Cell Biol"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.4049\/jimmunol.161.4.1853","article-title":"Signal-regulatory protein is selectively expressed by myeloid and neuronal cells","volume":"161","author":"Adams S","year":"1998","unstructured":"S Adams, , Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 161, 1853\u20131859 (1998).","journal-title":"J Immunol"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: Structure, function, and therapeutic target","volume":"32","author":"Barclay AN","year":"2014","unstructured":"AN Barclay, TK Van den Berg, The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: Structure, function, and therapeutic target. Annu Rev Immunol 32, 25\u201350 (2014).","journal-title":"Annu Rev Immunol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"E9626","DOI":"10.1073\/pnas.1705301114","article-title":"Humanized mouse model supports development, function and tissue residency of natural killer cells","volume":"114","author":"Herndler-Brandstetter D","year":"2017","unstructured":"D Herndler-Brandstetter, , Humanized mouse model supports development, function and tissue residency of natural killer cells. Proc Natl Acad Sci USA 114, E9626\u2013E9634 (October 25, 2017).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.coi.2014.01.008","article-title":"Manipulating immune cells for adoptive immunotherapy of cancer","volume":"27","author":"Darcy PK","year":"2014","unstructured":"PK Darcy, P Neeson, CS Yong, MH Kershaw, Manipulating immune cells for adoptive immunotherapy of cancer. Curr Opin Immunol 27, 46\u201352 (2014).","journal-title":"Curr Opin Immunol"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0092-8674(93)90133-B","article-title":"Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor","volume":"73","author":"Goodwin RG","year":"1993","unstructured":"RG Goodwin, , Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73, 447\u2013456 (1993).","journal-title":"Cell"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft M","year":"2009","unstructured":"M Croft, The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 9, 271\u2013285 (2009).","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-05-2883","article-title":"Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates","volume":"66","author":"Law CL","year":"2006","unstructured":"CL Law, , Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66, 2328\u20132337 (2006).","journal-title":"Cancer Res"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood-2006-07-034017","article-title":"Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities","volume":"109","author":"McEarchern JA","year":"2007","unstructured":"JA McEarchern, , Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109, 1185\u20131192 (2007).","journal-title":"Blood"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Batlevi CL","year":"2016","unstructured":"CL Batlevi, E Matsuki, RJ Brentjens, A Younes, Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13, 25\u201340 (2016).","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott AM","year":"2012","unstructured":"AM Scott, JD Wolchok, LJ Old, Antibody therapy of cancer. Nat Rev Cancer 12, 278\u2013287 (2012).","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil DN","year":"2016","unstructured":"DN Khalil, EL Smith, RJ Brentjens, JD Wolchok, The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol 13, 273\u2013290 (2016).","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","article-title":"Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis","volume":"76","author":"Weiskopf K","year":"2017","unstructured":"K Weiskopf, Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur J Cancer 76, 100\u2013109 (2017).","journal-title":"Eur J Cancer"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1093\/emboj\/19.24.6721","article-title":"SHPS-1 regulates integrin-mediated cytoskeletal reorganization and cell motility","volume":"19","author":"Inagaki K","year":"2000","unstructured":"K Inagaki, , SHPS-1 regulates integrin-mediated cytoskeletal reorganization and cell motility. EMBO J 19, 6721\u20136731 (2000).","journal-title":"EMBO J"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"18342","DOI":"10.1073\/pnas.1106550108","article-title":"CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction","volume":"108","author":"Zhao XW","year":"2011","unstructured":"XW Zhao, , CD47-signal regulatory protein-\u03b1 (SIRP\u03b1) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA 108, 18342\u201318347 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"e89140","DOI":"10.1172\/jci.insight.89140","article-title":"Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy","volume":"2","author":"Yanagita T","year":"2017","unstructured":"T Yanagita, , Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy. JCI Insight 2, e89140 (2017).","journal-title":"JCI Insight"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma","volume":"90","author":"Maloney DG","year":"1997","unstructured":"DG Maloney, , IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90, 2188\u20132195 (1997).","journal-title":"Blood"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu X","year":"2015","unstructured":"X Liu, , CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21, 1209\u20131215 (2015).","journal-title":"Nat Med"},{"key":"e_1_3_4_33_2","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng D","year":"2013","unstructured":"D Tseng, , Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA 110, 11103\u201311108 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_34_2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature22076","article-title":"SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin","volume":"544","author":"Chen J","year":"2017","unstructured":"J Chen, , SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493\u2013497 (2017).","journal-title":"Nature"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2016.12.012","article-title":"Neutrophils in homeostasis, immunity, and cancer","volume":"46","author":"Nicol\u00e1s-\u00c1vila JA","year":"2017","unstructured":"JA Nicol\u00e1s-\u00c1vila, JM Adrover, A Hidalgo, Neutrophils in homeostasis, immunity, and cancer. Immunity 46, 15\u201328 (2017).","journal-title":"Immunity"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian BZ","year":"2010","unstructured":"BZ Qian, JW Pollard, Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39\u201351 (2010).","journal-title":"Cell"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill SL","year":"2014","unstructured":"SL Highfill, , Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 6, 237ra67 (2014).","journal-title":"Sci Transl Med"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin RA","year":"2014","unstructured":"RA Franklin, , The cellular and molecular origin of tumor-associated macrophages. Science 344, 921\u2013925 (2014).","journal-title":"Science"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski TF","year":"2013","unstructured":"TF Gajewski, H Schreiber, YX Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14, 1014\u20131022 (2013).","journal-title":"Nat Immunol"},{"key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher TN","year":"2015","unstructured":"TN Schumacher, RD Schreiber, Neoantigens in cancer immunotherapy. Science 348, 69\u201374 (2015).","journal-title":"Science"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon H","year":"2016","unstructured":"H Salmon, , Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","first-page":"201026","DOI":"10.1155\/2010\/201026","article-title":"Myeloid cells in the tumor microenvironment: Modulation of tumor angiogenesis and tumor inflammation","volume":"2010","author":"Schmid MC","year":"2010","unstructured":"MC Schmid, JA Varner, Myeloid cells in the tumor microenvironment: Modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010, 201026 (2010).","journal-title":"J Oncol"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau O","year":"2016","unstructured":"O De Henau, , Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells. Nature 539, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"e_1_3_4_44_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature17038","article-title":"Metastatic colonization by circulating tumour cells","volume":"529","author":"Massagu\u00e9 J","year":"2016","unstructured":"J Massagu\u00e9, AC Obenauf, Metastatic colonization by circulating tumour cells. Nature 529, 298\u2013306 (2016).","journal-title":"Nature"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","article-title":"Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies","volume":"341","author":"Weiskopf K","year":"2013","unstructured":"K Weiskopf, , Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88\u201391 (2013).","journal-title":"Science"},{"key":"e_1_3_4_46_2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1107\/S0907444906019949","article-title":"HKL-3000: The integration of data reduction and structure solution\u2013From diffraction images to an initial model in minutes","volume":"62","author":"Minor W","year":"2006","unstructured":"W Minor, M Cymborowski, Z Otwinowski, M Chruszcz, HKL-3000: The integration of data reduction and structure solution\u2013From diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62, 859\u2013866 (2006).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_47_2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1107\/S090744490705024X","article-title":"Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard","volume":"64","author":"Terwilliger TC","year":"2008","unstructured":"TC Terwilliger, , Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr 64, 61\u201369 (2008).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: Model-building tools for molecular graphics","volume":"60","author":"Emsley P","year":"2004","unstructured":"P Emsley, K Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.1011777108","article-title":"VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration","volume":"108","author":"Razorenova OV","year":"2011","unstructured":"OV Razorenova, , VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA 108, 1931\u20131936 (2011).","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2003-06-2070","article-title":"New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population","volume":"103","author":"Jedema I","year":"2004","unstructured":"I Jedema, NM van der Werff, RM Barge, R Willemze, JH Falkenburg, New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103, 2677\u20132682 (2004).","journal-title":"Blood"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nbt822","article-title":"High-throughput engineering of the mouse genome coupled with high-resolution expression analysis","volume":"21","author":"Valenzuela DM","year":"2003","unstructured":"DM Valenzuela, , High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. Nat Biotechnol 21, 652\u2013659 (2003).","journal-title":"Nat Biotechnol"},{"key":"e_1_3_4_52_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00005072-198107000-00005","article-title":"Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines","volume":"40","author":"Bullard DE","year":"1981","unstructured":"DE Bullard, Jr SC Schold, SH Bigner, DD Bigner, Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40, 410\u2013427 (1981).","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1710877114","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1710877114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T15:27:07Z","timestamp":1693236427000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1710877114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":52,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2017,12,5]]}},"alternative-id":["10.1073\/pnas.1710877114"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1710877114","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,20]]},"assertion":[{"value":"2017-11-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}